Company / Cash & Equivalents
Orthofix Medical Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$82.0M
FY2025
5-year range
$33.1M / $96.3M
FY2021-FY2025
Trend
+147.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $82M.
Based on SEC 10-K filings.
$82M in FY2025 with a 5-year CAGR of +3.3%.
Improved from $51M to $82M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.3%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 147.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.0M | +147.8% |
| FY2024 | $33.1M | -34.7% |
| FY2023 | $50.7M | -42.3% |
| FY2022 | $87.8M | -8.8% |
| FY2021 | $96.3M | +38.1% |
| FY2020 | $69.7M | +0.1% |
| FY2019 | $69.6M | -14.2% |
| FY2018 | $81.2M | +105.1% |
| FY2017 | $39.6M | +7.5% |
| FY2016 | $36.8M | +27.3% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 28, 2026